The Fellow on Call: The Heme/Onc Podcast

This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we discuss how to we would approach each of these complicated scenarios. If you haven’t done so already, be sure to check out episodes 155 and 156!
Content:
- ITP management in pregnancy
- ITP management in a patient with new VTE
- ITP management in a patient with acute bleeding
- Refractory thrombocytopenia management despite multiple lines of therapy
- ITP management in a patient with TPO-RA side effect intolerance
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on the topics discussed here today!
Content:
- What are options after steroids?
- How to counsel patients on options?
- Is there a correct way to sequence available options?
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we go back to Classical Hematology! We previously discussed the initial workup and management of ITP in Episode 009, but now it’s time to dig deeper. What do we do once we make the diagnosis? How do we approach management when we have a new diagnosis?
Content:
- Refresher on diagnosis of ITP
- Response criteria
- What warrants a hospital admission vs. outpatient management?
- What is our approach to initial inpatient management?
- When is it safe to discharge a patient from the hospital?
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we are so excited to share the second episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis!
For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!
With fellowship application season around the corner, we thought that this was the perfect time to understand what program directors are looking for in their applicants. This time, we welcome Dr. Alice Ma, Hematology/Oncology Fellowship Director at UNC, and Dr. Gerald Hsu, Hematology/Oncology Fellowship Director at UCSF. Along with our guest hosts, Nick and Claire, we ask the tough questions that all of wish we could ask but never could. This is an episode you do not want to miss!
** This episode is created in partnership with The American Society of Hematology (https://www.hematology.org/), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoiesis (https://www.hematology.org/education/trainees/fellows/hematopoiesis)
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

Therapy, Maintenance, and Relapsed/Refractory Sequencing
This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting.
In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients.
If you have not already done so, be sure to check out Part 1 of this discussion!
Content:
- What are the practical implications of MRD-testing in myeloma treatment?
- How do we think about maintenance therapy in the present day?
- What therapies are on the horizon?
- How do we approach management of younger patients with relapsed/refractory disease?
- How do we approach bridging therapy?
** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows. As a special bonus, one of our guests, Dr. Mohyuddin, is an expert on Primum ready for your questions!
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube